DAMORA THERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- DAMORA THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $0.00.
- DAMORA THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $295.50M.
- DAMORA THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- DAMORA THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $171.00K, a 59.29% decline year-over-year.
- DAMORA THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2023 was $2.88M, a 467.26% increase from fiscal 2022.
- DAMORA THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2022 was $507.00K.
- DAMORA THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2020 was $86.36M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | |
| 2026-03-31 | $295.50M 10-Q · filed 2026-05-12 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $2.88M 10-K · filed 2025-03-19 |
| 2023-09-30 | $171.00K 10-Q · filed 2024-11-01 | $2.94M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $2.68M 10-Q · filed 2024-08-12 | $3.19M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $23.00K 10-Q · filed 2024-04-29 | $531.00K derived: sum of 4 quarters · filed 2024-04-29 |
| 2022-12-31 | $65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $507.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | $420.00K 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $23.00K 10-Q · filed 2023-07-31 | |
| 2020-12-31 | $86.36M 10-K · filed 2022-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |